Loading company…
SteadyMed develops therapies and drug delivery systems for pulmonary arterial hypertension.
SteadyMed develops treatments for pulmonary arterial hypertension (PAH), including therapies delivered through drug delivery systems. Its products are intended for patients and healthcare providers. Founded in 2005, the company is based in San Ramon, US, and is at the Public stage. In March 2015, it completed a trade sale involving Unither Pharmaceuticals for USD 216.00 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in